Trials / Conditions / Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy

24 registered clinical trials studyying Fuchs Endothelial Corneal Dystrophy — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Partial Range Of Field IOLs in DMEK-Enabled Procedures NCT07441616	Universitair Ziekenhuis Brussel	N/A
Enrolling By Invitation	Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years NCT07217249	Case Western Reserve University	N/A
Withdrawn	Assessment of Corneal Endothelial Function Following Hypoxic Stress NCT04175938	Massachusetts Eye and Ear Infirmary	Phase 1 / Phase 2
Recruiting	Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK) NCT07373821	University Hospital Heidelberg	N/A
Recruiting	DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy NCT07024693	Design Therapeutics, Inc.	Phase 2
Enrolling By Invitation	The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy NCT06969586	University Hospital Dubrava	—
Recruiting	Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endoth NCT06966167	Eye & ENT Hospital of Fudan University	—
Recruiting	Prognosis of Posterior Lamellar Keratoplasty, an Observational Cohort Study NCT06859411	Centre Hospitalier Régional Metz-Thionville	—
Completed	Prevalence of Fuchs Endothelial Corneal Dystrophy in a Population of Dermatology Patients. NCT07117071	Centre Hospitalier Universitaire de Saint Etienne	—
Completed	A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Desc NCT05826353	Kowa Research Institute, Inc.	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuch NCT05795699	Kowa Research Institute, Inc.	Phase 3
Completed	A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compa NCT05376176	Santen Inc.	Phase 2
Completed	Predictive Factors of Graft Detachment Following Dmek NCT05531760	Centre Hospitalier Régional Metz-Thionville	—
Withdrawn	Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects W NCT05052554	ProQR Therapeutics	Phase 1
Completed	Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema NCT04894110	Emmecell	Phase 1
Recruiting	Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy NCT04440280	Massachusetts Eye and Ear Infirmary	Phase 2
Completed	A Phase 1/ Phase 2 Study of TTHX1114(NM141) NCT04520321	Trefoil Therapeutics, Inc.	Phase 1 / Phase 2
Completed	Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FE NCT04250207	Kowa Research Institute, Inc.	Phase 2
Recruiting	SUCCESS Score Validation in Fuchs Dystrophy NCT07265388	Instituto Ramón y Cajal de Investigación Sanitaria	—
Unknown	The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK NCT04387331	Peter Wiedemann	—
Completed	Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. NCT03974230	Centre Hospitalier Universitaire de Saint Etienne	—
Completed	Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology NCT01979250	Aarhus University Hospital	N/A
Unknown	Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated En NCT02020044	Charite University, Berlin, Germany	N/A
Completed	Study of Endothelial Keratoplasty Outcomes NCT00800111	Cornea Research Foundation of America	N/A